Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04776876
Title Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Age Groups: senior | adult
Covered Countries

No variant requirements are available.